financetom
Business
financetom
/
Business
/
Rubrik shares fall as Microsoft-backed firm nears IPO lockup expiry
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Rubrik shares fall as Microsoft-backed firm nears IPO lockup expiry
Sep 10, 2024 11:59 PM

(Reuters) - Shares of Rubrik ( RBRK ) fell more than 6% on Tuesday, as the markets braced for the expiry of a lockup period tied to its initial public offering, clouding the Microsoft ( MSFT )-backed cybersecurity company's upbeat second-quarter revenue.

The lockup period expires on Wednesday and typically that would allow company insiders and pre-IPO investors to sell their shares, which often puts pressure on the stock price.

Rubrik's ( RBRK ) results, the second after it went public in April, indicate that businesses have been spending heavily to shield themselves from growing cyber attacks that have hit companies, including UnitedHealth Group, Microsoft ( MSFT ) and U.S. oilfield services firm Halliburton.

"While the pending IPO share-lockup expiry on Sept. 11 could cause some downward share price pressure, this report and the current robust cybersecurity spending environment confirm our positive Rubrik ( RBRK ) thesis," brokerage CIBC wrote in a note.

If losses hold, Rubrik ( RBRK ) will be on track to shed more than $350 million. The company had a market valuation of $5.77 billion as of Monday's close.

California-based Rubrik ( RBRK ) reported second-quarter revenue of about $205 million, compared with analysts' average estimate of $196.2 million, according to LSEG data.

Its adjusted loss per share for the quarter was 40 cents, compared with the estimates of a loss of 49 cents per share.

"We have helped hundreds of customers quickly come back online after the recent global IT disruption," Chief Executive Bipul Sinha said on a post-earnings call on Monday.

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Once a beacon of stability, Vietnam to name third president in a year
Once a beacon of stability, Vietnam to name third president in a year
Mar 22, 2024
HANOI, March 22 (Reuters) - Communist-ruled Vietnam is seeking its third president in little more than a year after the resignation of Vo Van Thuong, who was only elected last year after the sudden dismissal of his predecessor. With accumulated foreign direct investment higher than its gross domestic product, Vietnam's stability is crucial to multinationals with large operations in the...
Japan's union group Rengo announces biggest wage hikes on record
Japan's union group Rengo announces biggest wage hikes on record
Mar 22, 2024
TOKYO (Reuters) -Japanese firms have agreed to raise pay by 5.25% this year, the biggest rise under comparable data since 2013, the country's largest union group Rengo confirmed on Friday. The results of the closely-watched wage negotiations are announced in several stages, in which the blue-chip firms are first to wrap up their talks in mid-March. The second announcement on...
Cathie Wood's ARK Invest scoops up nearly 10,000 Reddit shares in debut
Cathie Wood's ARK Invest scoops up nearly 10,000 Reddit shares in debut
Mar 22, 2024
(Reuters) - Popular investor Cathie Wood's ARK Invest bought nearly 10,000 shares of Reddit ( RDDT ) in the social media platform's strong market debut on Thursday, an email from the asset manager showed. A total of 9,982 shares of the loss-making company was added to ARK Next Generation Internet ETF ( ARKW ) and ARK Fintech Innovation ETF (...
Hutchmed Begins Registration Stage for Phase 2/3 Trial of Investigational Autoimmune Disorder Drug
Hutchmed Begins Registration Stage for Phase 2/3 Trial of Investigational Autoimmune Disorder Drug
Mar 22, 2024
05:04 AM EDT, 03/22/2024 (MT Newswires) -- Hutchmed ( HCM ) said late Thursday it has started the registration stage for a phase 2/3 clinical trial of investigational drug sovleplenib for adult patients with warm antibody autoimmune hemolytic anemia in China. The move follows positive data from the proof-of-concept phase 2 stage of the trial and a consultation with the...
Copyright 2023-2026 - www.financetom.com All Rights Reserved